Venus Remedies touches roof on securing renewal of DSIR R&D recognition for VMRC
Venus Remedies is currently trading at upper limit of Rs. 1637.10, up by 77.95 points or 5.00% from its previous closing of Rs. 1559.15 on the BSE.
The scrip opened at Rs. 1609.65 and has touched a high and low of Rs. 1637.10 and Rs. 1559.15 respectively. So far 22043 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1,637.10 on 05-Jun-2026 and a 52 week low of Rs. 417.65 on 25-Jun-2025.
Last one week high and low of the scrip stood at Rs. 1,637.10 and Rs. 877.75 respectively. The current market cap of the company is Rs. 2188.31 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 4.00% and 54.24% respectively.
Venus Remedies has secured the renewal of in-house Research & Development (R&D) recognition from the Department of Scientific and Industrial Research (DSIR), Government of India, for its R&D unit, Venus Medicine Research Centre (VMRC).
DSIR recognition is granted to organisations that operate a dedicated in-house R&D unit with defined research objectives, qualified scientific staff, and separately accounted R&D expenditure. The renewal confirms that VMRC continues to meet these conditions.
The recognition supports VMRC's ongoing work in antimicrobial resistance, including the development of VRP-034, a novel polymyxin 8 formulation that holds USFDA Qualified Infectious Disease Product (QIDP) designation, and the GASAR resistance surveillance study.
.jpg)
